Androgen-deprivation therapy (ADT) with docetaxel may improve quality of life (QoL) at 12 months among patients with metastatic hormone-sensitive prostate cancer, according to research published in the Journal of Clinical Oncology.1

The randomized phase 3 E3805 study ( Identifier: NCT00309985) previously showed that combining docetaxel with ADT may improve overall survival vs ADT alone, though not among patients with low-volume metastatic hormone-sensitive disease. QoL is, furthermore, a critical factor for determining treatment.

For this analysis, researchers evaluated data from E3805 to determine whether patients assigned to the ADT or ADT plus docetaxel group had a better QoL at 12 months. Patients were asked to complete the Functional Assessment of Cancer Therapy-Prostate (FACT-P), the FACT-Taxane, the FACT-Fatigue, and the Brief Pain Inventory surveys at baseline and at 3, 6, 9, and 12 months.

Continue Reading

Of 790 enrolled patients, 397 received ADT plus docetaxel and 393 received ADT alone. Survey completion rates were high for the FACT-P: 90% at baseline, 86% at 3 months, 83% at 6 months, 78% at 9 months, and 77% at 12 months.

Related Articles

While patients who received docetaxel had a significant decrease in FACT-P-reported QoL between baseline and 3 months (P < .001), no difference in QoL was noted between baseline and 12 months. Compared with patients who received ADT only, patients in the ADT plus docetaxel group had a worse QoL at 3 months (P = .02) and an improved QoL at 12 months (P = .04). No significant difference was noted at 6 and 9 months.

Both groups saw declines in FACT-Taxane scores at all time points after baseline.

The authors concluded, however, that these “findings must be considered in the context of the population assessed and in the context of a simultaneously reported subgroup analysis that failed to find an improvement in overall survival in men with low-volume [disease treated with ADT plus docetaxel].”


  1. Morgans AK, Chen YH, Sweeney CJ, et al. Quality of life during treatment with chemohormonal therapy: analysis of E3805 chemohormonal androgen ablation randomized trial in prostate cancer. J Clin Oncol. 2018 Mar 9. doi: 10.1200/JCO.2017.75.3335 [Epub ahead of print]